000282599 001__ 282599
000282599 005__ 20251211100023.0
000282599 0247_ $$2doi$$a10.1111/bpa.70038
000282599 0247_ $$2pmid$$apmid:40935795
000282599 0247_ $$2ISSN$$a1015-6305
000282599 0247_ $$2ISSN$$a1750-3639
000282599 037__ $$aDZNE-2025-01357
000282599 041__ $$aEnglish
000282599 082__ $$a610
000282599 1001_ $$aStreit, Simon$$b0
000282599 245__ $$aNeurofilament light chain as a marker of peripheral nerve damage in vasculitic neuropathy? A cross-compartmental correlation analysis in patients undergoing nerve biopsy.
000282599 260__ $$aOxford$$bWiley-Blackwell$$c2025
000282599 3367_ $$2DRIVER$$aarticle
000282599 3367_ $$2DataCite$$aOutput Types/Journal article
000282599 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1765443526_17917
000282599 3367_ $$2BibTeX$$aARTICLE
000282599 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000282599 3367_ $$00$$2EndNote$$aJournal Article
000282599 520__ $$aVasculitic neuropathy remains challenging to diagnose and monitor because of its heterogeneous clinical and laboratory presentation. Blood-based biomarkers indicating nerve damage could serve as an additional diagnostic tool to ensure early diagnosis, precise therapeutic monitoring, and a more targeted anti-inflammatory treatment. A potential marker for this purpose is neurofilament light chain (NfL), a marker of neuroaxonal damage that is used as a biomarker in several diseases of the central and peripheral nervous system. NfL has also been suggested to reflect disease activity in patients with vasculitic neuropathy. However, its biodynamics and link to degeneration of peripheral nerve tissue remain unconfirmed. To investigate the usefulness of NfL as a marker of peripheral nerve damage in this context, we retrospectively assembled a cohort of 35 patients undergoing sural nerve biopsies (including patients with vasculitic neuropathy and other neuropathies). We then measured NfL in serum samples cryoarchived at the time of biopsy and correlated NfL levels with histological parameters. For our histological analysis, we quantified parameters of acute axonal degeneration and chronic axonal loss using a combination of manual, threshold-based, and supervised learning-based analyses. We found a significant positive correlation between parameters of acute axonal degeneration and serum-NfL levels that persisted after adjusting for age and concomitant central nervous system disease. We did not find a similar correlation with parameters of chronic axonal loss quantified in nerve biopsies. These findings support the value of NfL as a marker for acute axonal degeneration in patients with vasculitic neuropathy.
000282599 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000282599 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000282599 650_7 $$2Other$$abiomarker
000282599 650_7 $$2Other$$ahistopathology
000282599 650_7 $$2Other$$anerve biopsy
000282599 650_7 $$2Other$$aneurofilament light chain (NfL)
000282599 650_7 $$2Other$$avasculitic neuropathy
000282599 650_7 $$2Other$$avasculitis
000282599 7001_ $$aMeinhardt, Jenny$$b1
000282599 7001_ $$aGimber, Niclas$$b2
000282599 7001_ $$aKestenbach, John$$b3
000282599 7001_ $$aSiewert, Christin$$b4
000282599 7001_ $$aSchmoranzer, Jan$$b5
000282599 7001_ $$aMeisel, Christian$$b6
000282599 7001_ $$aRuprecht, Klemens$$b7
000282599 7001_ $$0P:(DE-2719)2812386$$aHeppner, Frank L$$b8$$udzne
000282599 7001_ $$0P:(DE-2719)2812030$$aKörtvélyessy, Péter$$b9$$udzne
000282599 7001_ $$00000-0002-1143-2103$$aStenzel, Werner$$b10
000282599 773__ $$0PERI:(DE-600)2029927-8$$a10.1111/bpa.70038$$gVol. 36, no. 1, p. e70038$$n1$$pe70038$$tBrain pathology$$v36$$x1015-6305$$y2025
000282599 8564_ $$uhttps://pub.dzne.de/record/282599/files/DZNE-2025-01357.pdf$$yRestricted
000282599 8564_ $$uhttps://pub.dzne.de/record/282599/files/DZNE-2025-01357.pdf?subformat=pdfa$$xpdfa$$yRestricted
000282599 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812386$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b8$$kDZNE
000282599 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812030$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b9$$kDZNE
000282599 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000282599 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2024-12-11$$wger
000282599 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-11
000282599 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-11
000282599 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2024-08-08T17:07:24Z
000282599 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2024-08-08T17:07:24Z
000282599 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2024-08-08T17:07:24Z
000282599 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-11
000282599 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-11
000282599 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-11
000282599 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-12-11
000282599 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-11
000282599 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-11
000282599 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-11
000282599 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBRAIN PATHOL : 2022$$d2024-12-11
000282599 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-11
000282599 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-11
000282599 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bBRAIN PATHOL : 2022$$d2024-12-11
000282599 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2024-12-11
000282599 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2024-12-11
000282599 9201_ $$0I:(DE-2719)1810007$$kAG Heppner$$lNeuroimmunology$$x0
000282599 9201_ $$0I:(DE-2719)5000006$$kAG Düzel$$lClinical Neurophysiology and Memory$$x1
000282599 980__ $$ajournal
000282599 980__ $$aEDITORS
000282599 980__ $$aVDBINPRINT
000282599 980__ $$aI:(DE-2719)1810007
000282599 980__ $$aI:(DE-2719)5000006
000282599 980__ $$aUNRESTRICTED